v3.26.1
Commitments and Contingencies - Additional Information (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Jun. 30, 2026
Nov. 30, 2024
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2025
Dec. 31, 2025
Loss Contingencies [Line Items]            
Common stock, shares issued 45,436,867   45,436,867     44,024,088
Grants research program $ 25,700,000   $ 25,700,000      
Grant earnings recognized       $ 800,000 $ 800,000  
Deferred grant earnings           $ 0
Vanderbilt License Agreement            
Loss Contingencies [Line Items]            
Upfront payment   $ 300,000        
Milestone payments     $ 0      
NeuroSolis, Inc. asset purchase agreement            
Loss Contingencies [Line Items]            
Upfront and development milestone payments $ 150,000          
Additional shares to be issued 35,476   35,476      
Initiation of Phase 2 Clinical Trial | NeuroSolis, Inc. asset purchase agreement            
Loss Contingencies [Line Items]            
Common stock, shares issued       26,607 26,607  
Maximum | Vanderbilt License Agreement            
Loss Contingencies [Line Items]            
Milestone payments   $ 52,400,000        
Maximum | Development and Regulatory Milestones | NeuroSolis, Inc. asset purchase agreement            
Loss Contingencies [Line Items]            
Common stock, shares issued 62,083   62,083